JPRN-UMIN000009512
Recruiting
未知
Evaluation of systemic Rituximab for treating orbital MALT lymphoma - Evaluation of systemic Rituximab for treating orbital MALT lymphoma
ConditionsOrbital MALT lymphoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Orbital MALT lymphoma
- Sponsor
- Osaka University Graduate School of Medicine
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The patients who have history of myocardial infarction and brain infarction.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
Completed
Not Applicable
Phase II study of Rituximab in Patients with Systemic Lupus ErythematosusSystemic lupus erythematosusJPRN-UMIN000000762Zenyaku Kogyo Co., Ltd.70
Active, not recruiting
Not Applicable
EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTPTHROMBOTIC THROMBOCYTOPENIC PURPURAMedDRA version: 9.1Level: LLTClassification code 10037562EUCTR2010-018794-38-ITFONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
Recruiting
Phase 2
Safety and Efficacy of Rituximab in patients with juvenile dermatomyositisJuvenile dermatomyositis.Juvenile dermatomyositisM33.0IRCT20231119060108N1Shahid Beheshti University of Medical Sciences7
Completed
Not Applicable
Analysis of Rituximab intensification therapy for low grade B-cell lymphoma refractory to BendamustineJPRN-UMIN000007110Tokyo women's medical university50